Molecular Genetics of Prostate Cancer: Clinical Applications

Journal of the National Medical Association

Volumn 90, Issue SUPPL., 1998, Pages

  Morton Jr , Ronald A ^a   Isaacs, William B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN;

CELL ADHESION; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; NEGRO; PROSTATE TUMOR; REVIEW;

AFRICAN CONTINENTAL ANCESTRY GROUP; CADHERINS; CELL ADHESION; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 0032215309     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Carter BS, Ewing CM, Ward WS, et al. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci. 1990;87:8751-8755.
2. Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM. Molecular biology of prostate cancer. Semin Oncol. 1994;21:514-521.
3. Collins VP, Kunimi K, Bergerheim U, Ekman P. Molecular genetics and human prostatic carcinoma. Acta Oncol. 1991;30:181-185.
4. Butz S, Larue L. Expression of catenins during mouse embryonic development and in adult tissues. Cell Adhes Commun. 1995;3:337-352.
5. Schneider S, Herrenknecht K, Butz S, Kemler R, Hausen P. Catenins in Xenopus embryogenesis and their relation to the cadherin-mediated cell-cell adhesion system. Development. 1993;118:629-640.
6. Schipper JH, Frixen UH, Behrens J, Unger A, Jahnke K, Birchmeier W. E-cadherin expression in squamous-cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res. 1991;51:6328-6337.
7. Frixen UH, Behrens J, Sachs M, et al. E-cadherm-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol. 1991;113:173-185.
8. Behrens J, Mareel MM, Van Roy FM, Birchmeier W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol. 1989;108:2435-2447.
9. Birchmeier W. E-cadherin as a tumor (invasive) suppressor gene. Bioessays. 1995;17:97-99.
10. Doki Y, Shiozaki H, Tahara H, et al. Correlation between E-cadherin expression and invasiveness in vitro in a human esophageal cancer cell line. Cancer Res. 1993;53:3421-3426.
11. Mareel M, Vleminckx K, Vermeulen S, Bracke M, Van Roy F. E-cadherin expression: a counterbalance for cancer cell invasion (review). Bull Cancer. 1992;79:347-355.
12. Birchmeier W. E-cadherin as a tumor (invasion) suppressor gene. [Review] [36 refs]. Bioessays. 1995;17:97-99.
13. Tamura S, Shiozaki H, Miyata M, et al. Decreased E-cadherin expression is associated with haematogenous recurrence and poor prognosis in patients with squamous cell carcinoma of the oesophagus. Br J Surg. 1996;83:1608-1614.
14. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol. 1993;5:806-811.
15. Bussemakers MJ, van Moorselaar RJ, Giroldi LA, et al. Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res. 1992;52:2916-2922.
16. Umbas R, Schalken JA, Aalders TW, et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 1992;52:5104-5109.
17. Umbas R, Isaacs WB, Bringuier PP, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 1994;54:3929-3933.
18. Morton RA, Ewing CM, Nagafuchi A, Tsukita S, Isaacs WB. Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells. Cancer Res. 1993;53:3585-3590.
19. Ewing CM, Ru N, Morton RA, et al. Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: corrleation with re-expression of alpha-catenin and restoration of E-cadherin function. Cancer Res. 1995;55:4813-4817.
20. Gingrich JR, Barrios RJ, Morton RA, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res. 1996;56:4096-4102.
21. Andenoro J, Madewell L, Rattan M, Wheeler T, Morton R. Prognostic value of immunohistochemical staining for E-cadherin and alpha catenin expression on prostate needle biopsies. J Urol. 1996;155:550A.
22. Makos M, Nelkin BD, Lerman MI, Latif F, Zbar B, Baylin SB. Distinct hypermethylation patterns occur at altered chromosome loci in human lung and colon cancer. Proc Natl Acad Sci. 1929;89:1929-1933.
23. Makos M, Nelkin BD, Chazin VR, Cavenee WK, Brodeur GM, Baylin SB. DNA hypermethylation is associated with 17p allelic loss in neural tumors. Cancer Research. 1993;53(12):2715-8.
24. Makos M, Nelkin BD, Reiter RE, et al. Regional DNA hypermethylation at D17S5 precedes 17p structural changes in the progression of renal tumors. Cancer Res. 1993;53:2719-2722.
25. Morton RA Jr, Watkins JJ, Bova GS, Wales MM, Baylin SB, Isaacs WB. Hypermethylation of chromosome 17p locus D17S5 in human prostate tissue. J Urol. 1996;156(2 Pt 1):512-516.
26. Wales MM, Biel MA, el Deiry W, et al. p53 activates expression of Hic-1, a new candidate tumour suppressor gene on 17p13.3. Nat Medicine. 1995;1:570-577.
27. Mettlin CJ, Murphy GP, McGinnis LS, Menck HR, The National Cancer Data Base report on prostate cancer. American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1995;76:1104-1112.
28. Pienta KJ, Demers R, Hoff M, Kau TY, Montie JE, Severson RK. Effect of age and race on the survival of men with prostate cancer in the metropolitan Detroit tri-county area, 1973 to 1987. Urology. 1995;45:93-101.
29. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst. 1986;76:45-48.
30. Ross RK, Berstein L, Lobo RA, et al. 5-alpha-reductase activity and risk of prostate cancer amongjapanese and US white and black males. Lancet. 1992;339:887-889.
31. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? Anticancer Res. 1990;10:1307-1311.
32. Whittemore AS, Kolonel LN, Wu AH, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst. 1995;87:652-661.
33. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med, 1993;118:793-803.
34. Kaul L, Heshmat MY, Kovi J, et al. The role of diet in prostate cancer. Nutr Cancer. 1987;9:123-128.
35. Heshmat MY, Kaul L, Kovi J, et al. Nutrition and prostate cancer: a case-control study. Prostate. 1985;6:7-17.
36. Godley PA, Campbell MK, Miller C, et al. Correlation between biomarkers of omega-3 fatty acid consumption and questionnaire data in African American and Caucasian United States males with and without prostatic carcinoma. Cancer Epidemiol Biomarkers Prev. 1996;5:115-119.
37. Dayal HH, Pollissar L, Dahlberg S. Race, socioeconomic status, and other prognostic factors for survival from prostate cancer. J Natl Cancer Inst. 1985;74:1001-1006.
38. Vijayakumar S, Karrison T, Weichselbaum RR, Chan S, Quadri SF, Awan AM. Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Cancer Epidemiol Biomarkers Prev. 1992;1:541-545.
39. Yu H, Harris RE, Wynder EL. Case-control study of prostate cancer and socioeconomic factors. Prostate. 1988;13:317-325.
40. Lyn D, Cherney BW, Lalande M, et al. A duplicated region is responsible for the poly (ADP-ribose) polymerase polymorphism, on chromosome 13, associated with a predispostion to cancer. Am J Hum Genet. 1993;52:124-134.
41. Doll JA, Suarez BK, Donis-Keller H. Association between prostate cancer in black Americans and an allele of the PADPRP pseudogene locus on chromsome 13. Am J Hum Genet. 1996;58:425-428.
42. Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM. Molecular biology of prostate cancer progression. Cancer Surv. 1995;23:19-32.
43. Isaacs WB, Carter BS, Ewing CM. Wild-type p53 suppresses growth of human prostatic cancer cells containing mutant p53 alleles. Cancer Res. 1991;51:4716-4720.
44. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. P53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 1993;53:3369-3373.